BOTHELL, Wash., Oct. 19, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that Amsterdam-based Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T cell immunotherapy treatments for blood cancers and inherited blood disorders, has incorporated the Company's clinical grade HypoThermosol cell and tissue storage and shipping medium into its collection process for donor leukocytes that forms the basis of Kiadis' ATIR101^™ T cell product targeting patients with various blood cancers.

In addition to Kiadis, a large majority of the currently active private and public cellular immunotherapy companies have adopted BioLife's biopreservation media products including HypoThermosol and CryoStor to extend stability and improve viability and functional recovery of starting material and manufactured cell products.

Mike Rice, BioLife's President & CEO, said, "We are very pleased to support Kiadis in their development of potentially life saving cellular immunotherapies for cancer patients.  It's very satisfying to see the clinical community focus on shelf life and viability as key criteria for potential commercialization of novel cell therapies.  HypoThermosol and our companion CryoStor freeze media are now embedded in over 200 pre-clinical validations and clinical trials of numerous cell-based products and therapies, with a significant concentration in applications of various T cell therapies."

About BioLife's Addressable Markets

In July 2015, Frost & Sullivan forecasted that the stem cell therapy market is expected to be worth $40 billion by 2020 and $180 billion by 2030. The Global Healthcare Cold Chain Logistics Market Report & Forecast published by the IMARC Group forecasts that the demand for cold chain packaging and instrumentation services will grow from $3.2 billion in 2013 to $5.1 billion in 2018. BioLife management believes its addressable market for small payload shippers and related monitoring devices is several hundred million dollars.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and smart shipping containers connected to a cloud hosted cold chain management app to improve the quality of delivery logistics for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol^® and CryoStor^® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning new products, the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, and, projected financial results and liquidity. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations
Daphne Taylor
Senior Vice President, Chief Financial Officer
(425) 402-1400 
dtaylor@biolifesolutions.com

SOURCE BioLife Solutions, Inc.